A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate the long-term safety and efficacy of RoActemra/Actemra
(tocilizumab) in combination with disease modifying anti-rheumatic drugs (DMARDs) in patients
with moderate to severe rheumatoid arthritis. Patients who successfully completed studies
WA17823 and WA18696 in South Africa are eligible to participate in this study. Patients will
be allowed DMARDs according to the treatment they received in the previous studies. Patients
will receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks. The anticipated time on
study treatment is 104 weeks.